Klinikverbund Suedwest GmbH

Clinical trial activity at this hospital-based research site focuses on neoplasms, with a strong emphasis on breast cancer and selected gastrointestinal cancers. The studies are designed to improve treatment choices, test new therapeutic combinations, and better identify which patients are most likely to benefit from adjuvant or neoadjuvant therapy.

• HER2-negative breast cancer and HR-positive, HER2-negative early breast cancer are being studied to assess whether newer treatment strategies can improve invasive disease-free survival and long-term outcomes.
• Triple-negative early breast cancer research is exploring whether adding immune-based treatment can strengthen response and reduce the risk of recurrence.
• Colon cancer stage II trials are evaluating whether additional treatment after surgery can improve disease-free survival in patients with detectable tumor markers.
• Rectal cancer stage II is also represented within the site's oncology portfolio, reflecting broader interest in refining care for colorectal cancer.

Overall, the research at Klinik für Frauenheilkunde und Geburtshilfe in Böblingen is centered on improving the effectiveness of cancer treatment and tailoring therapy to disease risk and tumor biology.

A major part of the site's clinical research is dedicated to breast cancer, especially HER2-negative and HR-positive disease. These trials aim to compare established treatment approaches with newer options, with the goal of improving survival, lowering relapse risk, and identifying more personalized care strategies for patients with early-stage disease.

• Studies in HR+/HER2- early breast cancer are examining whether ribociclib combined with endocrine therapy can improve outcomes beyond standard chemotherapy.
• Research in HER2-negative breast cancer is testing sacituzumab govitecan as a potential new treatment option.
• In triple-negative early breast cancer, investigators are evaluating whether combining therapies can produce stronger tumor control.

These studies reflect a clear focus on developing more effective and better-targeted treatment options for women with early breast cancer at Klinikverbund Suedwest GmbH.

The site also contributes to research in colorectal cancer, particularly colon cancer stage II and rectal cancer stage II. The main goal is to improve decisions about post-surgical treatment and to determine whether patients with higher-risk features may benefit from additional therapy after tumor removal.

• Colon cancer stage II studies are assessing whether patients with detectable ctDNA after surgery have better outcomes with added treatment.
• The research aims to refine adjuvant therapy choices and support more personalized follow-up care.

This area highlights the site's interest in using modern biomarkers and treatment strategies to improve disease-free survival in patients with early-stage gastrointestinal cancer.